Insulin Detemir

1
Insulin Detemir
Brands

DEA Class; Rx

Common Brand Names; Levemir, Levemir FlexTouch

  • Antidiabetics, Insulins; 
  • Antidiabetics, Long-Acting Insulins

Basal insulin analog administered subcutaneously once or twice daily
Used for type 1 diabetes mellitus (DM) in adult and pediatric patients 2 years and older and adults with type 2 DM
Advantages vs. NPH insulin include less variability in patient response, less weight gain, and a decrease in hypoglycemia risk, including both nocturnal and severe hypoglycemia

Indicated for the treatment of type 1 diabetes mellitus.

For the treatment of type 2 diabetes mellitus.
For the treatment of gestational diabetes or for the treatment of patients with pre-existing diabetes mellitus (type 1 or type 2) who are now pregnant.

 

Systemic allergic reactions

During episodes of hypoglycemia

Hypoglycemia

Headache

Influenza-like symptoms

Pallor

Palpitation

Tachycardia

Mental confusion

Redness

Urticaria

Weakness

Blurred vision

Itching

Hunger

Nausea

Lipodystrophy

Lipohypertrophy

Local allergic reaction

Hypokalemia

Localized cutaneous amyloidosis

Never share pen between patients even if needle is changed

Long-acting insulin; do not use for circumstances that require rapid-acting insulin

Use with caution in patients with decreased insulin requirements, including those with diarrhea, nausea/vomiting, malabsorption, hypothyroidism, renal impairment, or hepatic impairment

Rapid changes in serum glucose may induce symptoms of hypoglycemia

Frequent glucose monitoring and insulin dose reduction may be required with renal or hepatic impairment; not recommended during periods of rapidly declining renal or hepatic function, because of risk for prolonged hypoglycemia

May cause a shift in potassium from extracellular to intracellular space, possibly leading to hypokalemia; caution when coadministered with potassium-lowering drugs or conditions that may decrease potassium

Use with caution in patients with increased insulin requirements, including those with fever, hyperthyroidism, trauma, or infection or who have undergone surgery

Lower dose when used in combination with a GLP-1 receptor agonist to minimize the risk of hypoglycemia

Available data from published studies and postmarketing case reports in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Available data from published literature demonstrate that exogenous human insulin products, are transferred into human milk; there are no published reports of adverse reactions, including hypoglycemia, in breastfed infants exposed to exogenous human insulin products, including this drug, in breastmilk

Specific maximum dosage information is not available. Individualize dosage based on careful monitoring of blood glucose and other clinical parameters in all patient populations.

Insulin detemir rDNA origin

injectable solution

  • 100 units/mL (10mL vial)

prefilled syringe

  • 100 units/mL (3mL FlexTouch)
DrugsAce
Logo